This inventor holds 10 USPTO granted patents. Top assignee: Dainippon Ink and Chemicals, Incorporated. Active years: 1989-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1989-2001
Title: Masayoshi Abe: Innovator in Quinolinone Derivatives
Introduction
Masayoshi Abe is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of quinolinone derivatives. With a total of 10 patents to his name, Abe's work has the potential to impact the treatment of allergic diseases.
Latest Patents
Abe's latest patents include a quinolinone derivative and a method for preparing the same, as well as an anti-allergic agent. The invention relates to a simple method for preparing a quinolinone derivative, which is effective as a medicine for treating allergic diseases. The method involves the reaction of an amide derivative with a basic agent, leading to intramolecular ring formation. The quinolinone derivative is characterized by a specific general formula, which includes various substituents that enhance its medicinal properties.
Career Highlights
Masayoshi Abe is currently employed at Dainippon Ink and Chemicals, Incorporated. His work at this company has allowed him to focus on innovative solutions in the field of pharmaceuticals. Abe's research has led to the development of novel amide derivatives that serve as intermediates in the preparation of quinolinone derivatives.
Collaborations
Abe has collaborated with notable coworkers, including Hidetsugu Takagaki and Mitsuru Sakai. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Masayoshi Abe's contributions to the field of medicinal chemistry, particularly through his work on quinolinone derivatives, highlight his role as an influential inventor. His innovative methods and collaborative efforts continue to pave the way for advancements in the treatment of allergic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile